{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/724-US10,975,364(Active) re (Done on website already).pdf"}, "page_content": "The Sequence Listing file entitled \u201cmkcp406sequencelisting\u201dhaving a size of 72,282 bytes and a creation date of Dec. 4, 2020, is incorporated herein by reference in its entirety.\n\nin an embodiment, the modified protein is expressed in the cell, or the cell is contacted with the modified protein and a guide RNA having a region complementary to a selected portion of the genome of the cell.\n\nTECHNICAL FIELD\n\nin a third aspect, the invention pertains to a kit comprising the modified protein. In an embodiment, the kit comprises a modified Streptococcus aureus Cas9 (SaCas9) protein with a mutation at an N413 position, and optionally one or more of a nuclear localization sequence, a cell penetrating peptide sequence, an affinity tag and/or a fusion base editor protein.\n\nThe present invention relates to a modified protein and its use in altering the genome of a cell. Particularly, but not exclusively, the invention relates to a modified Streptococ- cus aureus Cas9 (SaCas9) protein and its use in genomic engineering, genome targeting and genome editing tech- nologies.\n\nin an embodiment, the modified protein comprises amino acid sequence as defined in SEQ ID NO: 1 or homologue thereof. In a further embodiment, the modified protein comprises an amino acid sequence as defined in SEQ ID NO: 2 or a homologue thereof.\n\nBACKGROUND OF THE INVENTION", "type": "Document"}}